The project of this Spanish and Japanese small molecule CDMO (Contract Development & Manufacturing Organization) will bring an investment of 100 million US dollars, increasing a 30% API production capacity and creating 100 new jobs by first half of 2024.
Barcelona, April 6, 2022 – AGC Pharma Chemicals, based in Spain and Japan, manufacturing small molecule Active Pharmaceutical Ingredients (APIs) and intermediates, has decided to expand even more the site of Malgrat de Mar, Barcelona.
The expansion of the CDMO means a 7,500 square meters floor of building area and the implementation of new reactors with a volume from 1.5 to 7.5 m3, including the production capability to handle pharmaceutical compounds HPAPIs. In addition, the company has already planned another important investment soon, and for that the new building will have additional space for this future project.
In terms of Sustainability, as a member of the Responsible Care® Program, a global chemical industry’s voluntary initiative, AGC Pharma Chemicals will build up and operate the new plant minimizing its impacts to the community and the environment.
Also, the enterprise has recently invested in a larger R&D building, in the transformation to multi-purpose concept plant and in a micronizer unit. Thanks to all these projects, the CDMO company will be fully capable of producing a wide range of APIs and intermediates, offering the knowledge of handling flourine as one of their services.
The small molecule CDMO market is growing at over 7% annually, while the number of contracts handled by the companies are growing at an even faster rate. With this capacity expansion AGC Pharma Chemicals is prepared to satisfy this strong demand of the industry, focusing on their mission: to improve people´s lives by bringing their best quality products.
ABOUT US
AGC Pharma Chemicals is a Global Contract Development and Manufacturing Organization (CDMO), based in Spain and Japan, manufacturing small molecule Active Pharmaceutical Ingredients (APIs) and intermediates with solid business growth and financial stability as a part of AGC Group.
AGC Group is a global business conglomerate with over 200 companies, more than 55,800 employees and extending into over 30 countries with net sales of € 12,731 million (Y120 = €1) during 2020.
Under its medium-term management plan AGC plus-2023, the AGC Group has positioned its Life Science business, including its small molecule CDMO services, as one of its strategic businesses.